Vertex Pharmaceuticals (VRTX) Q4 2024 Annual Earnings
Vertex Pharmaceuticals reported Q4 2024 revenue of $2.9B, beat analyst consensus of $2.8B by $127.8M. Diluted EPS came in at $3.98, missed the $4.02 consensus by $0.04. Vertex Pharmaceuticals reports across 3 business segments, led by Cystic Fibrosis (CF), Hematology and Pain Management, and Specialty Pipeline Programs.
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Vertex Pharmaceuticals's Q4 2024 earnings report.
Vertex Pharmaceuticals (VRTX) reported Q4 2024 earnings on February 10, 2025 after market close.
Vertex Pharmaceuticals reported revenue of $2.9B and diluted EPS of $3.98 for Q4 2024.
Revenue beat the consensus estimate of $2.8B by $127.8M. EPS missed the consensus estimate of $4.02 by $0.04.
You can read the 10-K periodic report (0000875320-25-000053) directly on SEC EDGAR. The filing index links above go to sec.gov.